0001209191-21-017237.txt : 20210303
0001209191-21-017237.hdr.sgml : 20210303
20210303182246
ACCESSION NUMBER: 0001209191-21-017237
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210301
FILED AS OF DATE: 20210303
DATE AS OF CHANGE: 20210303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Layman Melissa
CENTRAL INDEX KEY: 0001806204
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36287
FILM NUMBER: 21711162
MAIL ADDRESS:
STREET 1: C/O FLEXION THERAPEUTICS, INC.
STREET 2: 10 MALL ROAD, STE. 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Flexion Therapeutics Inc
CENTRAL INDEX KEY: 0001419600
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 MALL ROAD
STREET 2: SUITE 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
BUSINESS PHONE: (781) 305-7777
MAIL ADDRESS:
STREET 1: 10 MALL ROAD
STREET 2: SUITE 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-01
0
0001419600
Flexion Therapeutics Inc
FLXN
0001806204
Layman Melissa
C/O FLEXION THERAPEUTICS, INC.
10 MALL ROAD, SUITE 301
BURLINGTON
MA
01803
0
1
0
0
Chief Commercial Officer
Common Stock
2021-03-01
4
A
0
20100
0.00
A
108476
D
Performance Restricted Stock Unit Award
0.00
2021-03-01
4
A
0
30150
0.00
A
Common Stock
30150
30150
D
Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan.
Represents the maximum number of shares deliverable under the performance restricted stock unit award.
Upon confirmation by the Board of Directors or the Compensation Committee thereof that a specified amount of 2021 revenues from ZILRETTA product sales is achieved, 25% of the shares eligible for vesting under the restricted stock unit award shall vest in 2022 upon confirmation of such revenues being achieved and thereafter on January 1 of the subsequent three years so that all of such shares will have vested on January 1, 2025.
/s/ Mark S. Levine, Attorney-in-Fact
2021-03-03